Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Armand

Blood

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Blood|April 3, 2015
Immune checkpoint blockade in hematologic malignanciesPhilippe Armand
Blood|September 24, 2024
The current landscape of frontline large B-cell lymphoma trialsDavid Qualls, Philippe Armand, Gilles Salles
Blood|March 18, 2024
Frontline management of mantle cell lymphomaChristine E Ryan, Philippe Armand, Ann S LaCasce
Blood|May 4, 2018
Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evilCharles Herbaux, Reid Merryman, Steven Devine, et al.
Blood|August 31, 2016
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapyBruce D Cheson, Stephen Ansell, Larry Schwartz, et al.
Blood|January 20, 2007
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantationPhilippe Armand, Haesook T Kim, Corey S Cutler, et al.
Blood|March 31, 2017
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphomaLakshmi Nayak, Fabio M Iwamoto, Ann LaCasce, et al.
Blood|November 8, 2019
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negativeSanjay S Patel, Jason L Weirather, Mikel Lipschitz, et al.
Blood|May 12, 2017
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphomaPier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, et al.
Blood|August 29, 2009
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donorsJohn Koreth, Kristen E Stevenson, Haesook T Kim, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Blood|April 3, 2015
Immune checkpoint blockade in hematologic malignanciesPhilippe Armand
Blood|September 24, 2024
The current landscape of frontline large B-cell lymphoma trialsDavid Qualls, Philippe Armand, Gilles Salles
Blood|March 18, 2024
Frontline management of mantle cell lymphomaChristine E Ryan, Philippe Armand, Ann S LaCasce
Blood|May 4, 2018
Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evilCharles Herbaux, Reid Merryman, Steven Devine, et al.
Blood|August 31, 2016
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapyBruce D Cheson, Stephen Ansell, Larry Schwartz, et al.
Blood|January 20, 2007
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantationPhilippe Armand, Haesook T Kim, Corey S Cutler, et al.
Blood|March 31, 2017
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphomaLakshmi Nayak, Fabio M Iwamoto, Ann LaCasce, et al.
Blood|November 8, 2019
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negativeSanjay S Patel, Jason L Weirather, Mikel Lipschitz, et al.
Blood|May 12, 2017
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphomaPier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, et al.
Blood|August 29, 2009
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donorsJohn Koreth, Kristen E Stevenson, Haesook T Kim, et al.
Pageof 5